GlassScriptPhysician profile
Stacey W Mayeaux
NPI 1013986892
$3,433.02
in general payments reported to CMS, 2019-2025
42 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $362 · 2021: $523 · 2022: $704 · 2023: $597 · 2024: $403 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $357.91 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.97 | 2020-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $259.27 | 2021-2023 | Trintellix |
| Abbvie INC. | $242.39 | 2021-2023 | |
| Amgen INC. | $198.99 | 2019-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $176.62 | 2019-2025 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $161.50 | 2021-2023 | |
| Novo Nordisk INC | $157.27 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $140.92 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Ardelyx, INC. | $116.37 | 2024-2025 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $112.28 | 2022-2025 | Zoryve, Seglentis |
| Lilly USA, LLC | $100.89 | 2019-2025 | Mounjaro, Jardiance |
| Supernus Pharmaceuticals, INC. | $89.83 | 2021-2023 | Xyosted, Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.72 | 2022-2025 | Xifaxan, Relistor, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $86.41 | 2023-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Mayeaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.